{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:16:11Z","timestamp":1782854171962,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clcc.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:43:08Z","timestamp":1590493388000},"page":"e226-e234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials"],"prefix":"10.1016","volume":"19","author":[{"given":"Atul","family":"Batra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2020.05.005_bib1","author":"World Health Organization"},{"key":"10.1016\/j.clcc.2020.05.005_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2020.05.005_bib3","author":"Canadian Cancer Society"},{"key":"10.1016\/j.clcc.2020.05.005_bib4","first-page":"177","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2020.05.005_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","article-title":"Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies","volume":"16","author":"Keum","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clcc.2020.05.005_bib6","author":"Statistics Canada"},{"key":"10.1016\/j.clcc.2020.05.005_bib7","first-page":"1","article-title":"Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline summary","volume":"5","author":"Costas-Chavarri","year":"2019","journal-title":"J\u00a0Glob Oncol"},{"issue":"suppl 6","key":"10.1016\/j.clcc.2020.05.005_bib8","doi-asserted-by":"crossref","first-page":"vi64","DOI":"10.1093\/annonc\/mdt354","article-title":"Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Labianca","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/80.1.30","article-title":"Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01","volume":"80","author":"Wolmark","year":"1988","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2020.05.005_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199002083220602","article-title":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","volume":"322","author":"Moertel","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.05.005_bib11","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.1999.17.11.3553","volume":"17","author":"Wolmark","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib12","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.1200\/JCO.2004.00.5686","article-title":"Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089","volume":"23","author":"Haller","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib13","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1200\/JCO.2003.10.065","article-title":"Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial","volume":"21","author":"Andre","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib14","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1200\/JCO.2007.12.2234","article-title":"Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1","volume":"25","author":"Andr\u00e9","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib15","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.05.005_bib16","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.05.005_bib17","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly\u00a0bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib18","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer","volume":"29","author":"Haller","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib19","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib20","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib21","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib22","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib24","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"7 suppl","key":"10.1016\/j.clcc.2020.05.005_bib25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/1097-0142(19941001)74:7+<1995::AID-CNCR2820741702>3.0.CO;2-Y","article-title":"Cancer in older persons. Magnitude of the problem\u2014how do we apply what we know?","volume":"74","author":"Yancik","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2020.05.005_bib26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.0.CO;2-W","article-title":"Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study","volume":"82","author":"Yancik","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2020.05.005_bib27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2020.05.005_bib28","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.3747\/co.26.5625","article-title":"Role of real-world evidence in informing cancer care: lessons from colorectal cancer","volume":"26","author":"Batra","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib29","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.clcc.2020.05.005_bib30","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clon.2019.05.003","article-title":"Generalisability of common oncology clinical trial eligibility criteria in the real world","volume":"31","author":"Karim","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.clcc.2020.05.005_bib32","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jamcollsurg.2013.04.018","article-title":"AJCC\u20137th edition staging criteria for colon cancer: do the complex modifications improve prognostic assessment?","volume":"217","author":"Hari","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.clcc.2020.05.005_bib35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ypmed.2016.04.009","article-title":"Disparities in the prevalence of comorbidities among US adults by state Medicaid expansion status","volume":"88","author":"Akinyemiju","year":"2016","journal-title":"Prev Med"},{"key":"10.1016\/j.clcc.2020.05.005_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2105\/AJPH.2009.173112","article-title":"Effects of socioeconomic status on colon cancer treatment accessibility and survival in Toronto, Ontario, and San Francisco, California, 1996-2006","volume":"101","author":"Gorey","year":"2011","journal-title":"Am J Public Health"},{"key":"10.1016\/j.clcc.2020.05.005_bib37","author":"Canadian Partnership Against Cancer"},{"key":"10.1016\/j.clcc.2020.05.005_bib38","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.3747\/co.25.3978","article-title":"Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non\u2013small-cell lung cancer patients?","volume":"25","author":"Al-Baimani","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12032-018-1176-6","article-title":"Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy","volume":"35","author":"Angeles","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cllc.2012.03.008","article-title":"Identifying barriers associated with enrollment of patients with lung cancer into clinical trials","volume":"14","author":"Horn","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clcc.2020.05.005_bib41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2407-9-130","article-title":"Eligibility of patients with advanced non\u2013small cell lung cancer for phase III chemotherapy trials","volume":"9","author":"Vardy","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2020.05.005_bib43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jgo.2018.07.012","article-title":"The use of chemotherapy in older patients with stage II and III colon cancer: variation by age and era of diagnosis","volume":"10","author":"Green","year":"2019","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clcc.2020.05.005_bib44","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1001\/jama.294.21.2703","article-title":"Adjuvant chemotherapy for stage III colon cancer: implications of race\/ethnicity, age, and differentiation","volume":"294","author":"Jessup","year":"2005","journal-title":"JAMA"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820300785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820300785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:56Z","timestamp":1761520016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002820300785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1533002820300785"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2020.05.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}